• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Aytu BioPharma Inc.

    5/26/23 1:52:28 PM ET
    $AYTU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AYTU alert in real time by email
    SC 13D 1 tm2317127d1_sc13d.htm SC 13D

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13D

    (Amendment No.)

     

    (Rule 13d-101)

     

    Under the Securities Exchange Act of 1934

     

    AYTU BIOPHARMA, INC.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    054754858

    (CUSIP NUMBER)

     

    Taki Vasilakis

    130 Main St. 2nd Floor

    New Canaan, CT 06840

    (203) 308-4440

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    May 26, 2023

    (Date of event which requires filing of this statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g) check the following box ¨.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     

     

     

     

    CUSIP No.   054754858 13D  

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Nantahala Capital Management, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ¨

    (b) ¨

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS*

     

    AF

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT

    TO ITEM 2(d) or 2(e)

    ¨

     

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Massachusetts

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7

    SOLE VOTING POWER

     

    0 

    8

    SHARED VOTING POWER

     

    271,595

    9

    SOLE DISPOSITIVE POWER

     

    0 

    10

    SHARED DISPOSITIVE POWER

     

    271,595

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    271,595

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES

    CERTAIN SHARES*

    ¨

     

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    7.2%

    14

    TYPE OF REPORTING PERSON*

     

    IA, OO

     

     

     

     

    CUSIP No.   054754858 13D  

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Wilmot B. Harkey

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ¨

    (b) ¨

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS*

     

    AF

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT

    TO ITEM 2(d) or 2(e)

    ¨

     

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7

    SOLE VOTING POWER

     

    0 

    8

    SHARED VOTING POWER

     

    271,595

    9

    SOLE DISPOSITIVE POWER

     

    0 

    10

    SHARED DISPOSITIVE POWER

     

    271,595

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    271,595

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES

    CERTAIN SHARES*

    ¨

     

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    7.2%

    14

    TYPE OF REPORTING PERSON*

     

    HC, IN

     

     

     

     

    CUSIP No.   054754858 13D  

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Daniel Mack

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ¨

    (b) ¨

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS*

     

    AF

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT

    TO ITEM 2(d) or 2(e)

    ¨

     

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7

    SOLE VOTING POWER

     

    0 

    8

    SHARED VOTING POWER

     

    271,595

    9

    SOLE DISPOSITIVE POWER

     

    0 

    10

    SHARED DISPOSITIVE POWER

     

    271,595

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    271,595

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES

    CERTAIN SHARES*

    ¨

     

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    7.2%

    14

    TYPE OF REPORTING PERSON*

     

    HC, IN

     

     

     

     

    CUSIP No.   054754858 13D  

     

    SCHEDULE 13D

     

    This Schedule 13D (this “Schedule 13D”) is being filed on behalf of Nantahala Capital Management, LLC, a Massachusetts limited liability company (“Nantahala”), Mr. Wilmot B. Harkey and Mr. Daniel Mack, the principals of Nantahala (collectively, the “Reporting Persons”), relating to Common Stock, par value $0.0001 per share (the “Common Stock”), of Aytu BioPharma, Inc. a Delaware corporation (the “Issuer”).

     

    This Schedule 13D relates to Common Stock of the Issuer purchased by Nantahala through the accounts of certain private funds and managed accounts (collectively, the “Nantahala Investors”). Nantahala serves as the investment adviser to the Nantahala Investors and may direct the vote and dispose of the 271,595 shares of Common Stock held by the Nantahala Investors. As the principals of Nantahala, Mr. Harkey and Mr. Mack may direct the vote and disposition of the 271,595 shares of Common Stock held by the Nantahala Investors.

     

      Item 1. Security and Issuer

     

    Securities acquired: Common Stock, par value $0.0001 per share (the “Common Stock”).

     

      Issuer: Aytu BioPharma, Inc.

    373 Inverness Parkway, Suite 206

    Englewood, Colorado 80112

     

      Item 2. Identity and Background

     

    (a) This Schedule 13D is jointly filed by Nantahala, Mr. Harkey and Mr. Mack. Because Nantahala is the investment adviser to the Nantahala Investors and Mr. Harkey and Mr. Mack are the principals and managing members of Nantahala, the Reporting Persons may be deemed, pursuant to Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “Act”), to be the beneficial owners of all of the shares of Common Stock held by the Nantahala Investors. The Reporting Persons are filing this Schedule 13D jointly, solely pursuant to Rule 13d-1(k)(1), and expressly disclaim that they form any “group” under Section 13(d)(3) of the Act. In addition, Qianqian Zhong is the Chief Financial Officer and Taki Vasilakis is the Chief Compliance Officer (each of Ms. Zhong and Mr. Vasilakis, an “Other Officer” and collectively, the “Other Officers”) of Nantahala.

     

    (b) The principal place of business for each of the Reporting Persons and the Other Officers is 130 Main Street 2nd Floor, New Canaan, CT 06840.

     

    (c) The principal occupation of Mr. Harkey is serving as a principal of Nantahala. The principal occupation of Mr. Mack is serving as a principal of Nantahala. The principal business of Nantahala is acting as the investment adviser to the Nantahala Investors. The principal occupations of the Other Officers are the Nantahala positions set forth above.

     

    (d) During the last five years, none of the Reporting Persons or Other Officers have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e) During the last five years, none of the Reporting Persons or Other Officers have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, were or are subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

     

     

     

    (f) Nantahala is organized under the laws of the State of Massachusetts. Mr. Harkey is a citizen of the United States of America. Mr. Mack is a citizen of the United States of America. Ms. Zhong is a citizen of China. Mr. Vasilakis is a citizen of the United States of America.

     

      Item 3. Source and Amount of Funds

     

    Nantahala acquired the shares of Common Stock for the Nantahala Investors in January 2023 using the Nantahala Investors’ cash on hand. The shares of Common Stock are held in a margin accounts with an unaffiliated brokerage firm.

     

      Item 4. Purpose of the Transaction

     

    Nantahala originally purchased shares of Common Stock for the Nantahala Investors in January 2023 based on the Reporting Persons’ belief that the Common Stock was undervalued and represented an attractive investment opportunity.

     

    Subsequently, at the invitation of the Issuer’s management and board, the Reporting Persons have been invited to participate in discussions regarding means to preserve and enhance shareholder value. At the request of the Issuer, the Reporting Persons expect to participate in discussions with the Issuer’s management and board and their advisers, either singly or together with other shareholders and interested parties, regarding the Issuer’s business, governance, financial condition, operations, prospects, expected results, and strategic alternatives. Among other topics, those discussions are expected to address, without limitation, the issuer’s near-term capitalization needs, including the role of the Reporting Persons and others in potential Issuer financing transactions, and may further address potential extraordinary corporate transactions, dispositions of some or all of the Issuer’s assets, transitions within the board or management, changes in the Issuer’s capitalization, and the Issuer’s continuation as a public company and maintenance of its stock exchange listing.

     

    No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer’s financial position and investment strategy, the price levels of the Common Stock, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, engaging in communications with management and the Board, engaging in discussions with shareholders of the Issuer and others about the Issuer and the Reporting Persons’ investment, making proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure (including Board composition) or operations of the Issuer, purchasing additional Common Stock, or changing their intention with respect to any and all matters referred to in Item 4.

     

      Item 5. Interest in Securities of the Issuer

     

    (a)      The aggregate percentage of Common Stock beneficially owned by the Reporting Persons is based upon 3,780,179 shares of Common Stock outstanding, which is the total number of shares of Common Stock outstanding as of May 8, 2023, as reported in the Issuer’s 10-Q filed with the Securities and Exchange Commission (the “SEC”) on May 11, 2023.

     

    Nantahala, as the investment adviser of the Nantahala Investors, may be deemed to beneficially own the 271,595 shares of Common Stock held by the Nantahala Investors, representing approximately 7.2% of the issued and outstanding shares of Common Stock of the Issuer.

     

    In addition, Mr. Harkey and Mr. Mack, as principals of Nantahala, the investment adviser of the Nantahala Investors, may also be deemed to beneficially own the 271,595 shares of Common Stock beneficially owned by the Nantahala Investors, representing approximately 7.2% of the issued and outstanding shares of Common Stock of the Issuer.

     

     

     

     

    (b)       Nantahala, Mr. Harkey and Mr. Mack have the shared power to vote and dispose of the Common Stock reported in this Schedule 13D.

     

    (c)       There have been no transactions in the shares of Common Stock during the past sixty (60) days by the Reporting Persons or the Other Officers.

     

    (d)       The Nantahala Investors hold the shares of Common Stock reported herein. No person other than the Nantahala Investors is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Common Stock.

     

    (e)       Not applicable.

     

      Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

     

    There are no contracts, arrangements, understandings, or relationships among the Reporting Persons or Other Officers, or between any of the Reporting Persons or Other Officers and any other person, with respect to the securities of the Issuer.

     

      Item 7. Material to be Filed as Exhibits

     

    Exhibit 99.1 Joint Filing Agreement, dated May 26, 2023.

     

     

     

     

    Signatures

     

    After reasonable inquiry and to the best of their knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: May 26, 2023

     

    NANTAHALA CAPITAL MANAGEMENT, LLC  
         
         
    By: /s/ Taki Vasilakis  
      Taki Vasilakis  
      Chief Compliance Officer  
         
         
         
    /s/ Wilmot B. Harkey  
    Wilmot B. Harkey  
         
         
    /s/ Daniel Mack  
    Daniel Mack  

     

     

     

    Get the next $AYTU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AYTU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AYTU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

      DENVER, CO / ACCESSWIRE / January 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that CEO, Josh Disbrow, will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.The fireside chat will take place at 10:00 a.m. Eastern Time on Monday, January 13, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/health2025/ or directly at https://lythampartners.com/health2025/aytu. A replay of the fireside chat will also be available through same links.1

      1/6/25 9:00:00 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Disclosure Notification

      DENVER, CO / ACCESSWIRE / December 3, 2024 / SUMMARY NOTICE OF PENDENCY OF DERIVATIVE ACTION, AGREEMENT OF SETTLEMENT AND RELEASE WITH RESPECT TO CERTAIN PARTIES, AND SETTLEMENT HEARING IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE LITIGATION STYLED WITMER V. ARMISTICE CAPITAL LLC, ET AL., NO. 2022-0807-MTZ (THE "ACTION").TO: ALL CURRENT RECORD HOLDERS AND BENEFICIAL OWNERS OF COMMON STOCK OF AYTU BIOPHARMA, INC. ("AYTU" OR THE "COMPANY") (NASDAQ:AYTU) AS OF OCTOBER 9, 2024 (THE "RECORD DATE") ("CURRENT AYTU SHAREHOLDERS").YOU ARE HEREBY NOTIFIED that the Settling Parties to the Action have reached a settlement ("Settlement") to resolve the issues raised in the Action against Defendants

      12/3/24 11:45:00 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

      DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced it ranked 380th on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year."We are honored to be recognized for the fourth consecutive year as a member of the Deloitte Technology Fast 500 list of the most rapidly growing companies," commented Josh Disbrow, Chief Executive Officer of Aytu BioPharma. "During fiscal 2024, we continued to successfully reposition

      11/22/24 9:00:00 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Financials

    Live finance-specific insights

    See more
    • Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

      Net income of $1.5 millionAdjusted EBITDA1 of $1.9 millionADHD Portfolio net revenue up 1% to $15.3 millionPediatric Portfolio net revenue up 54% sequentially$20.1 million cash balance at September 30, 2024Organizational changes and operating optimization plan implemented to further streamline operations, reduce expenses, and accelerate path to consistent cash flowRyan Selhorn promoted to Chief Financial OfficerCompany to host conference call and webcast today, November 13, 2024, at 4:30 p.m. Eastern time DENVER, CO / ACCESSWIRE / November 13, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today ann

      11/13/24 4:05:00 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024

      DENVER, CO / ACCESSWIRE / November 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its first quarter of fiscal 2025, after the market close on Wednesday, November 13, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, November 13, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.Conference Call DetailsDate and Time: Wednesday, November 13, 2024, at 4:30 p.m. Eastern timeCall-in Information: Interested parties can access the conference call by dialing (877) 545-

      11/6/24 5:20:00 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results

      Full year fiscal 2024 consolidated net revenue of $81.0 million; Rx Segment net revenue of $65.2 millionFull year fiscal 2024 ADHD Portfolio net revenue up 23% compared to fiscal 2023Full year fiscal 2024 adjusted EBITDA1 improved to $9.2 million, up by $5.7 million compared to fiscal 2023$20.0 million cash balance at June 30, 2024Company expects Rx Segment net revenue and adjusted EBITDA growth in fiscal 2025 from current levelsCompany to host conference call and webcast today, September 26, 2026, at 4:30 p.m. Eastern timeDENVER, CO / ACCESSWIRE / September 26, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel ther

      9/26/24 4:15:00 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Leadership Updates

    Live Leadership Updates

    See more
    • Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

      Webcasted presentation to take place at 1:10pm ETDENVER, CO / ACCESSWIRE / November 30, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference on December 7, 2023.Mr. Disbrow will conduct a presentation and subsequently open the floor to questions. Please submit your questions in advance to [email protected]'s presentation will be on Thursday, December 7th at 1:10pm ET. To register to stream the presentation live, visit this LINK or visit the Company's website.If attendees are not able to

      11/30/23 8:00:00 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Appoints Mark Oki as Chief Financial Officer

      ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced that Mark Oki will join Aytu as the company's chief financial officer effective January 17, 2022. Mr. Oki will serve as a member of Aytu's executive committee and will report to Josh Disbrow, chief executive officer. Mr. Oki will provide leadership and oversight of the company's financial operations and planning, accounting, information technology and select other functions."On behalf of the entire company, I am delighted to welcome Mark to Aytu and look forward to partnering with him as we

      1/4/22 8:00:00 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights

      - Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company -- Added late-stage pediatric onset rare disease asset, protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) to development pipeline -- Record quarter for consumer health division with revenue reaching $8.4 million and Rx division revenue up 9% over same quarter last year -- Grew leadership team with three executives including CFO, Rich Eisenstadt - - Management to host live conference call and webcast today at 4:30 p.m. ET -ENGLEWOOD, CO / ACCESSWIRE / May 17, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commerciali

      5/17/21 4:01:00 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Aytu BioPharma Inc.

      DEFA14A - AYTU BIOPHARMA, INC (0001385818) (Filer)

      3/28/25 4:03:19 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Aytu BioPharma Inc.

      DEF 14A - AYTU BIOPHARMA, INC (0001385818) (Filer)

      3/28/25 4:02:19 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Aytu BioPharma Inc.

      10-Q - AYTU BIOPHARMA, INC (0001385818) (Filer)

      2/12/25 4:12:32 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $AYTU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $AYTU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $AYTU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chief Executive Officer Disbrow Joshua R. bought $19,500 worth of shares (15,000 units at $1.30), increasing direct ownership by 21% to 86,591 units (SEC Form 4)

      4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

      3/3/25 1:35:04 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Commercial Officer Pyszczymuka Greg converted options into 209 shares, increasing direct ownership by 0.89% to 23,602 units (SEC Form 4)

      4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

      3/31/25 4:34:24 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Selhorn Ryan J converted options into 105 shares, increasing direct ownership by 0.66% to 16,000 units (SEC Form 4)

      4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

      3/3/25 7:22:47 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Disbrow Joshua R. bought $19,500 worth of shares (15,000 units at $1.30), increasing direct ownership by 21% to 86,591 units (SEC Form 4)

      4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

      3/3/25 1:35:04 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Aytu BioPharma Inc.

      SC 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)

      11/13/24 5:36:50 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Aytu BioPharma Inc.

      SC 13D/A - AYTU BIOPHARMA, INC (0001385818) (Subject)

      6/18/24 4:30:29 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aytu BioPharma Inc. (Amendment)

      SC 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)

      2/13/24 4:25:46 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Aytu BioPharma with a new price target

      Cantor Fitzgerald initiated coverage of Aytu BioPharma with a rating of Overweight and set a new price target of $11.00

      3/30/21 6:27:35 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care